ACD679 / AlzeCure - LARVOL DELTA

Poster presentation with the Alzstatin platform now available on AlzeCure’s website (PRNewswire) - "AlzeCure, presents how the mechanisms in the research platform Alzstatin work and shows that the target mechanism within the platform is suitable as a new treatment for Alzheimer's disease. Furthermore, data show that the class of drug substances being developed within AlzeCure's platform, so-called gamma-secretory modulators, selectively affect the production of toxic Abeta-amyloid, without affecting the cleavage of other substrates that potentially play an important role in normal physiological function....Preparatory preclinical safety pharmacological and toxicological studies are underway with the primary drug candidate in the Alzstatin platform, ACD679."

Preclinical • Alzheimer's Disease • CNS Disorders